Trial Profile
A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary)
- Indications Hyperphosphataemia; Kidney disorders
- Focus Therapeutic Use
- Sponsors Keryx Biopharmaceuticals
- 19 Dec 2014 New trial record